Serenatis Bio

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.

Biomia

The company develops nature-inspired small molecule therapeutics to treat central nervous system disorders for patients with mental health conditions and chronic pain.

Monument Therapeutics

This biotech company develops digital biomarkers and targeted drugs to treat patients with schizophrenia and other neurological conditions.

Brandaris

This biotechnology company develops neuropsychiatric drug candidates to treat patients with mental health disorders including depression and anxiety.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Synendos Therapeutics

This company develops small molecule inhibitors to treat patients with central nervous system disorders, such as anxiety and post-traumatic stress disorder.

Mindstate Design Labs

This biotechnology company develops custom psychedelic therapeutics using an artificial intelligence platform to treat mental health conditions for patients with various psychiatric disorders.